Valuation : GENFIT

Market Cap 689M 802M 648M 592M 1.11B 75.81B 1.11B 7.69B 2.97B 38.82B 3.01B 2.94B 124B P/E 2026 *
35.6x
P/E 2027 * 91.5x
Enterprise Value 638M 742M 600M 548M 1.02B 70.18B 1.03B 7.12B 2.75B 35.94B 2.79B 2.73B 114B EV / Sales 2026 *
6.37x
EV / Sales 2027 * 5.02x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-3.62%
Current month-3.41%
1 month-3.41%
6 months+60.00%
Current year+155.40%
1 month 13.6
Extreme 13.6
14.08
Current year 5.2
Extreme 5.205
14.34
1 year 3.19
Extreme 3.19
14.34
3 years 3.19
Extreme 3.19
14.34
5 years 3.19
Extreme 3.19
14.34
10 years 3.19
Extreme 3.19
14.34
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-3.41%-1.81% - - 801M
-1.16%-2.77%-1.68%+13.85% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
-0.96%-2.31%+15.75%+45.41% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.54%-1.30%+12.02%+31.14% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -1.22%+0.48%+73.69%+109.93% 30.55B
Weighted average by Cap. -0.95%+0.05%+89.18%+128.66%

Financials

2026 *2027 *
Net sales 100M 117M 94.24M 86.03M 161M 11.02B 161M 1.12B 432M 5.64B 438M 428M 17.97B 124M 144M 117M 107M 199M 13.64B 200M 1.38B 535M 6.99B 542M 530M 22.25B
Net income 22.88M 26.6M 21.52M 19.64M 36.74M 2.52B 36.85M 255M 98.62M 1.29B 99.9M 97.72M 4.1B 6.8M 7.91M 6.4M 5.84M 10.92M 748M 10.95M 75.83M 29.31M 383M 29.69M 29.04M 1.22B
Net Debt -51.12M -59.44M -48.08M -43.89M -82.08M -5.62B -82.35M -570M -220M -2.88B -223M -218M -9.17B -66.17M -76.95M -62.24M -56.81M -106M -7.28B -107M -738M -285M -3.73B -289M -283M -11.87B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
26-09-07 13.60 -3.41% 0
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.78EUR
Average target price
15.90EUR
Spread / Average Target
+15.38%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!